Q4 2024 Precigen Inc Earnings Call Transcript
Key Points
- Precigen Inc (PGEN) is on the verge of commercializing its lead asset, PRGN-2012, with a PDUFA date set for August 27, 2025.
- PRGN-2012 has demonstrated a 51% complete response rate in clinical trials, with durable responses lasting up to 24 months.
- The company has built a dedicated GMP facility for in-house manufacturing, ensuring better control over production and costs.
- Precigen Inc (PGEN) has established a comprehensive commercialization strategy, including a partnership with a proven leader in rare disease launches.
- The company has a strong financial position, with cash reserves expected to support operations well into 2026.
- Precigen Inc (PGEN) reported a net loss of $126.2 million for 2024, an increase from the previous year's loss.
- The confirmatory trial for PRGN-2012 will not be completed by the PDUFA date, with results expected in 2026 or 2027.
- There is uncertainty regarding the FDA's pre-approval inspection timing, which is part of the regulatory process.
- The company faces challenges in ensuring payer access and pricing strategies for PRGN-2012, with potential utilization management by payers.
- Precigen Inc (PGEN) has yet to publish data from its Phase I study of PRGN-3006, with no specific timeline provided for its release.
Good evening and welcome to the Precigen's Full Year 2024 Financial Results and Business Update Call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over to Steve Harasym from Investor Relations. Please go ahead.
Thank you, Alan, and thank you for everyone joining us this afternoon. With me today are Dr. Helen Sabzevari, President and CEO of Precigen; Harry Thomasian our CFO; and Phil Tennant, our Chief Commercial Officer; and Ratul Shah, our Chief Operating Officer. Before we begin, let me briefly review our forward-looking statements. During today's call, we will make various forward-looking statements.
Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ from those indicated by our forward-looking statements. Please read the safe harbor statement contained in our most recent SEC filings
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
